Pieris Pharmaceuticals, Inc.
PIRS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $84 | $17 | $39 | $118 |
| Short-Term Investments | $0 | $9 | $21 | $0 |
| Receivables | $0 | $1 | $6 | $3 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $4 | $12 | $8 | $7 |
| Total Curr. Assets | $88 | $39 | $73 | $128 |
| Property Plant & Equip (Net) | $0 | $0 | $21 | $23 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $0 | $0 | $0 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $1 | $3 |
| Total NC Assets | $0 | $0 | $22 | $26 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $88 | $39 | $95 | $154 |
| Liabilities | – | – | – | – |
| Payables | $5 | $3 | $4 | $9 |
| Short-Term Debt | $0 | $0 | $1 | $1 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $21 | $25 |
| Other Curr. Liab. | $7 | $9 | $11 | $16 |
| Total Curr. Liab. | $12 | $12 | $37 | $51 |
| LT Debt | $0 | $0 | $12 | $14 |
| Deferred Rev, NC | $0 | $0 | $19 | $38 |
| Deferred Tax Liab, NC | $0 | $0 | -$19 | -$38 |
| Other NC Liab. | $14 | $0 | $19 | $38 |
| Total NC Liab. | $14 | $0 | $31 | $52 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $13 | $15 |
| Total Liabilities | $26 | $12 | $68 | $103 |
| Equity | – | – | – | – |
| Pref Stock | $88 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$94 | -$315 | -$290 | -$257 |
| AOCI | $0 | $0 | -$0 | $1 |
| Other Equity | $0 | $342 | $319 | $307 |
| Total Equity | $63 | $27 | $28 | $51 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $88 | $39 | $95 | $154 |
| Net Debt | -$84 | -$17 | -$26 | -$103 |